Elevated copeptin is a prognostic factor for mortality even in patients with renal dysfunction

International Journal of Cardiology

Volumn 221, Issue , 2016, Pages 327-332

  Engelbertz, Christiane ^a   Brand, Eva ^a   Fobker, Manfred ^a   Fischer, Dieter ^a   Pavenstädt, Hermann ^a   Reinecke, Holger ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Chronic kidney disease; Copeptin; Coronary artery disease; Mortality; Prognosis

Indexed keywords

COPEPTIN; CREATININE; GLYCOPEPTIDE;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL MORTALITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; REPEAT PROCEDURE; ANGIOGRAPHY; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; EPIDEMIOLOGY; GERMANY; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; REGISTER; SEVERITY OF ILLNESS INDEX; STATISTICS; STATISTICS AND NUMERICAL DATA;

AGED; ANGIOGRAPHY; CORONARY ARTERY DISEASE; CREATININE; FEMALE; GERMANY; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGISTRIES; RENAL INSUFFICIENCY, CHRONIC; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC;

EID: 84977654423     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.07.058     Document Type: Article

References (27)

1. [1] Morgenthaler, N.G., Struck, J., Alonso, C., Bergmann, A., Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin. Chem. 52 (2006), 112–119.
2. [2] Morgenthaler, N.G., Copeptin: a biomarker of cardiovascular and renal function. Congest. Heart Fail. 16:Suppl. 1 (2010), S37–S44.
3. [3] Morgenthaler, N.G., Struck, J., Jochberger, S., Dünser, M.W., Copeptin: clinical use of a new biomarker. Trends Endocrinol. Metab. 19 (2008), 43–49.
4. [4] Katan, M., Christ-Crain, M., The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med. Wkly., 140, 2010, w13101.
5. [5] Khan, S.Q., Dhillon, O.S., O'Brien, R.J., et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation 115 (2007), 2103–2110.
6. [6] Katan, M., Fluri, F., Morgenthaler, N.G., et al. Copeptin: a novel, independent prognostic marker in patients with ischemic stroke. Ann. Neurol. 66 (2009), 799–808.
7. [7] Afzali, D., Erren, M., Pavenstädt, H.J., et al. Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. Clin. Res. Cardiol. 102 (2013), 755–763.
8. [8] Lippi, G., Plebani, M., Di Somma, S., et al. Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin. Clin. Chem. Lab. Med. 50 (2012), 243–253.
9. [9] Reichlin, T., Hochholzer, W., Stelzig, C., et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J. Am. Coll. Cardiol. 54 (2009), 60–68.
10. [10] Bhandari, S.S., Loke, I., Davies, J.E., Squire, I.B., Struck, J., Ng, L.L., Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin. Sci. 116 (2009), 257–263.
11. [11] Meijer, E., Bakker, S.J., Halbesma, N., de Jong, P.E., Struck, J., Gansevoort, R.T., Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int. 77 (2010), 29–36.
12. [12] Brand, E., Pavenstädt, H., Schmieder, R.E., et al. The Coronary Artery Disease and Renal Failure (CAD-REF) registry: trial design, methods, and aims. Am. Heart J. 166 (2013), 449–456.
13. [13] Reinecke, H., Breithardt, G., Engelbertz, C., et al. Baseline characteristics and prescription patterns of standard drugs in patients with angiographically determined coronary artery disease and renal failure (CAD-REF Registry). PLoS One, 11, 2016, e0148057.
14. [14] von Haehling, S., Papassotiriou, J., Morgenthaler, N.G., et al. Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease. Int. J. Cardiol. 162 (2012), 27–32.
15. [15] Bosselmann, H., Egstrup, M., Rossing, K., et al. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: a long term follow-up study. Int. J. Cardiol. 170 (2013), 202–207.
16. [16] Colbert, G., Jain, N., de Lemos, J.A., Hedayati, S.S., Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD. Clin. J. Am. Soc. Nephrol. 10 (2015), 515–529.
17. [17] Bjurman, C., Petzold, M., Venge, P., Farbemo, J., Fu, M.L., Hammarsten, O., High-sensitive cardiac troponin, NT-proBNP, hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease. Clin. Biochem. 48 (2015), 302–307.
18. [18] Kelly, D., Squire, I.B., Khan, S.Q., et al. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction. J. Card. Fail. 14 (2008), 739–745.
19. [19] Malyszko, J., Przybylowski, P., Koc-Zorawska, E., et al. Copeptin in relation to New York Heart Association class in heart transplant recipients and kidney transplant recipients. Transplant. Proc. 42 (2010), 4259–4262.
20. [20] Przybylowski, P., Malyszko, J., Malyszko, J.S., Copeptin in heart transplant recipients depends on kidney function and intraventricular septal thickness. Transplant. Proc. 42 (2010), 1808–1811.
21. [21] Jarai, R., Mahla, E., Perkmann, T., et al. Usefulness of pre-operative copeptin concentrations to predict post-operative outcome after major vascular surgery. Am. J. Cardiol. 108 (2011), 1188–1195.
22. [22] Meijer, E., Bakker, S.J.L., de Jong, P.E., et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 88 (2009), 561–567.
23. [23] Fenske, W., Wanner, C., Allolio, B., et al. Copeptin levels associate with cardiovascular events in patients with ESRD a type 2 diabetes mellitus. J. Am. Soc. Nephrol. 22 (2011), 782–790.
24. [24] Maisel, A., Xue, Y., Shah, K., et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the Biomarkers in Acute Heart Failure (BACH) study. Circ. Heart Fail. 4 (2011), 613–620.
25. [25] Pozsonyi, Z., Förhécz, Z., Gombos, T., Karádi, I., Jánoskuti, L., Prohászka, Z., Copeptin (C-terminal pro arginine-vasopressin) is an independent long-term prognostic marker in heart failure with reduced ejection fraction. Heart Lung Circ. 24 (2015), 359–367.
26. [26] Yang, J.G., Li, J., Lu, C., Hasimu, B., Yang, Y., Hu, D., Chronic kidney disease, all-cause mortality and cardiovascular mortality among Chinese patients with established cardiovascular disease. J. Atheroscler. Thromb. 17 (2010), 395–401.
27. [27] Schrimpf, C., Gillmann, H.J., Sahlmann, B., et al. Renal function interferes with copeptin in prediction of major adverse cardiac events in patients undergoing vascular surgery. PLoS One, 10, 2015, e0123093.